Compass Therapeutics (CMPX) Stock: Buy, Sell, or Hold?
CMPX - Compass Therapeutics, Inc. Common Stock
$2.00
-0.05 (-2.44%)
▼
5d:
-15.61%
30d:
-15.61%
90d:
-0.5%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 8, 2026 at $2.29 · last confirmed Sep 11, 2026
Strength: 8.5/10
Get Alerted When CMPX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CMPX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CMPX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CMPX is currently trading at $2.00, which is considered oversold relative to its 30-day fair value range of $2.08 to $2.45.
Technical Outlook: Technically, CMPX is in a strong uptrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.92 (+345.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CMPX is in a strong uptrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.92 (+345.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.08 -
$2.45
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 345.8% below Wall St target ($8.92)
- NEUTRAL: Bottoming setup forming (47/100) — watch for confirmation
- CAUTION: 5-day price weakness (-15.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.08 -
$2.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.51
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.74
Wall Street Target
$8.92
(+345.8%)
Share & Embed Analysis
Last updated: September 13, 2026 9:34 AM ET
Data refreshes hourly during market hours. Next update: 10:34 AM
Data refreshes hourly during market hours. Next update: 10:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CMPX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
